Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis

Interferon (INF) β 1a 22 or 44 μg (Rebif(®)) administered s.c. 3 times a week (t.i.w) is a well established immunomodulating treatment for relapsing remitting multiple sclerosis (RRMS). This review focuses on its mechanisms of action, evidence of efficacy, safety, and tolerability. Several pharmacod...

Descripción completa

Detalles Bibliográficos
Autores principales: Manfredonia, Francesco, Pasquali, Livia, Dardano, Angela, Iudice, Alfonso, Murri, Luigi, Monzani, Fabio
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518386/
https://www.ncbi.nlm.nih.gov/pubmed/18728744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518386/
https://www.ncbi.nlm.nih.gov/pubmed/18728744

Ejemplares similares